WallStSmart

AngioDynamics Inc (ANGO)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 927% more annual revenue ($3.22B vs $313.73M). WST leads profitability with a 16.9% profit margin vs -10.0%. ANGO appears more attractively valued with a PEG of 1.41. WST earns a higher WallStSmart Score of 65/100 (C+).

ANGO

Hold

43

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.0Quality: 5.3
Piotroski: 5/9Altman Z: 0.14

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ANGOUndervalued (+37.7%)

Margin of Safety

+37.7%

Fair Value

$18.26

Current Price

$11.94

$6.32 discount

UndervaluedFair: $18.26Overvalued
WSTSignificantly Overvalued (-56.0%)

Margin of Safety

-56.0%

Fair Value

$157.79

Current Price

$314.50

$156.71 premium

UndervaluedFair: $157.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANGO1 strengths · Avg: 8.0/10
Price/BookValuation
2.9x8/10

Reasonable price relative to book value

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

ANGO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$462.77M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-18.1%2/10

ROE of -18.1% — below average capital efficiency

Free Cash FlowQuality
$-4.13M2/10

Negative free cash flow — burning cash

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
44.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ANGO

The strongest argument for ANGO centers on Price/Book. PEG of 1.41 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : ANGO

The primary concerns for ANGO are EPS Growth, Market Cap, Return on Equity.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.

Key Dynamics to Monitor

ANGO profiles as a turnaround stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (65/100 vs 43/100), backed by strong 16.9% margins and 21.0% revenue growth. ANGO offers better value entry with a 37.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AngioDynamics Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AngioDynamics, Inc. designs, manufactures and sells various medical, surgical and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company is headquartered in Latham, New York.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?